CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025
CASI Pharmaceuticals (NASDAQ:CASI), a clinical-stage biopharmaceutical company specializing in therapies for organ transplant rejection and autoimmune diseases, has announced its participation in the upcoming Cantor Global Healthcare Conference.
CEO David Cory will engage in a fireside chat on September 3, 2025, at 11:30 AM ET in New York City. The company will also conduct one-on-one investor meetings during the conference. Investors can access the live webcast through CASI's website, with a replay available for 90 days following the event.
CASI Pharmaceuticals (NASDAQ:CASI), azienda biofarmaceutica in fase clinica specializzata in terapie per il rigetto d'organo e le malattie autoimmuni, ha comunicato la sua partecipazione al prossimo Cantor Global Healthcare Conference.
Il CEO David Cory parteciperà a una fireside chat il 3 settembre 2025 alle 11:30 ET a New York City. La società terrà inoltre incontri individuali con investitori durante la conferenza. Gli investitori potranno seguire la diretta streaming dal sito di CASI; la replica sarà disponibile per 90 giorni dopo l'evento.
CASI Pharmaceuticals (NASDAQ:CASI), una compañía biofarmacéutica en fase clínica especializada en terapias para el rechazo de órganos y enfermedades autoinmunes, ha anunciado su participación en la próxima Cantor Global Healthcare Conference.
El CEO David Cory participará en una fireside chat el 3 de septiembre de 2025 a las 11:30 AM ET en la ciudad de Nueva York. La compañía también mantendrá reuniones uno a uno con inversores durante la conferencia. Los inversores podrán acceder a la transmisión en vivo a través del sitio web de CASI; la repetición estará disponible durante 90 días tras el evento.
CASI Pharmaceuticals (NASDAQ:CASI)는 장기 이식 거부 반응 및 자가면역 질환 치료제에 특화된 임상 단계 바이오제약사로, 다가오는 Cantor Global Healthcare Conference에 참여한다고 발표했습니다.
CEO David Cory는 2025년 9월 3일 동부 시간(ET) 기준 오전 11시 30분에 뉴욕에서 열리는 파이어사이드 채팅에 참석합니다. 회사는 컨퍼런스 기간 동안 투자자와의 1:1 미팅도 진행할 예정입니다. 투자자들은 CASI 웹사이트를 통해 라이브 웹캐스트를 시청할 수 있으며, 행사는 종료 후 90일간 다시보기로 제공됩니다.
CASI Pharmaceuticals (NASDAQ:CASI), une société biopharmaceutique en phase clinique spécialisée dans les traitements du rejet d'organe et des maladies auto-immunes, a annoncé sa participation à la prochaine Cantor Global Healthcare Conference.
Le PDG David Cory participera à une « fireside chat » le 3 septembre 2025 à 11h30 (heure ET) à New York. La société tiendra également des réunions individuelles avec des investisseurs pendant la conférence. Les investisseurs pourront accéder au webdiffusion en direct via le site de CASI ; un replay sera disponible pendant 90 jours après l'événement.
CASI Pharmaceuticals (NASDAQ:CASI), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien gegen Organabstoßung und Autoimmunerkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden Cantor Global Healthcare Conference angekündigt.
CEO David Cory wird am 3. September 2025 um 11:30 Uhr ET in New York City an einem Fireside Chat teilnehmen. Das Unternehmen wird außerdem Einzelgespräche mit Investoren während der Konferenz führen. Investoren können das Live-Webcast über die CASI-Website verfolgen; eine Aufzeichnung steht 90 Tage nach der Veranstaltung zur Verfügung.
- None.
- None.
SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will participate in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM ET in New York City. CASI will also host one-on-one meetings with investors at the conference.
A live webcast of the fireside chat will be available on the CASI Pharmaceuticals website at www.casipharmaceuticals.com under the "Investors" tab. A replay of the webcast will be available for 90 days after the live event.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.
CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) and plans to initiate the study in third quarter of 2025.
More information on CASI is available at www.casipharmaceuticals.com.
COMPANY CONTACT:
Ingrid Choong, PhD
650-619-6115
ingridc@casipharmaceuticals.com
SOURCE: CASI Pharmaceuticals
View the original press release on ACCESS Newswire
FAQ
When is CASI Pharmaceuticals (CASI) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access CASI Pharmaceuticals' presentation at the Cantor Conference?
What type of meetings will CASI Pharmaceuticals host at the Cantor Healthcare Conference?
What is CASI Pharmaceuticals' main business focus?
